Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know

Group 1 - Aligos Therapeutics, Inc. (ALGS) closed at $8.77, with a 1.5% gain over the past four weeks, and a mean price target of $95 suggests a potential upside of 983.2% [1] - The mean estimate includes three short-term price targets with a standard deviation of $69.46, indicating variability; the lowest estimate of $50.00 suggests a 470.1% increase, while the highest target of $175.00 indicates a potential surge of 1895.4% [2] - Analysts agree that ALGS is expected to report better earnings than previously estimated, which strengthens the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for ALGS has increased by 14.9% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - ALGS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for price movement [14]